
Sign up to save your podcasts
Or
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
4
77 ratings
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
130 Listeners
13 Listeners
319 Listeners
862 Listeners
494 Listeners
692 Listeners
18 Listeners
272 Listeners
254 Listeners
3,321 Listeners
260 Listeners
87 Listeners
1,082 Listeners
186 Listeners
515 Listeners
320 Listeners
59 Listeners
25 Listeners
288 Listeners